Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Schuind

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Human Vaccines|August 18, 2009
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 yearsMark H Einstein, Mira Baron, Myron J Levin, et al.
Vaccine|June 6, 2007
Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataScott Halperin, Katrin S Kohl, Jane Gidudu, et al.
Human Vaccines|November 4, 2011
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda M Ferguson, et al.
The Journal of Infectious Diseases|June 6, 2020
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary VaccinationAndrew Hastie, Grégory Catteau, Adaora Enemuo, et al.
Vaccine|April 30, 2019
Safety of AS03-adjuvanted influenza vaccines: A review of the evidenceCatherine Cohet, Robbert van der Most, Vincent Bauchau, et al.
The Pediatric Infectious Disease Journal|June 4, 2005
Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccinePenelope H Dennehy, Rebecca C Brady, Scott A Halperin, et al.
Lancet (London, England)|April 25, 2006
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialDiane M Harper, Eduardo L Franco, Cosette M Wheeler, et al.
Open Forum Infectious Diseases|January 27, 2022
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of ProtectionJasur Danier, Andrea Callegaro, Jyoti Soni, et al.
The Pediatric Infectious Disease Journal|August 6, 2011
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trialCosette M Wheeler, Bryan M Harvey, Michael E Pichichero, et al.
Vaccines|June 28, 2023
Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling StudyEsperança Lourenço Guimarães, Assucênio Chissaque, Clint Pecenka, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Human Vaccines|August 18, 2009
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 yearsMark H Einstein, Mira Baron, Myron J Levin, et al.
Vaccine|June 6, 2007
Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety dataScott Halperin, Katrin S Kohl, Jane Gidudu, et al.
Human Vaccines|November 4, 2011
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda M Ferguson, et al.
The Journal of Infectious Diseases|June 6, 2020
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary VaccinationAndrew Hastie, Grégory Catteau, Adaora Enemuo, et al.
Vaccine|April 30, 2019
Safety of AS03-adjuvanted influenza vaccines: A review of the evidenceCatherine Cohet, Robbert van der Most, Vincent Bauchau, et al.
The Pediatric Infectious Disease Journal|June 4, 2005
Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccinePenelope H Dennehy, Rebecca C Brady, Scott A Halperin, et al.
Lancet (London, England)|April 25, 2006
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialDiane M Harper, Eduardo L Franco, Cosette M Wheeler, et al.
Open Forum Infectious Diseases|January 27, 2022
Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6-35 Months of Age: Statistical Evaluation of a Correlate of ProtectionJasur Danier, Andrea Callegaro, Jyoti Soni, et al.
The Pediatric Infectious Disease Journal|August 6, 2011
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trialCosette M Wheeler, Bryan M Harvey, Michael E Pichichero, et al.
Vaccines|June 28, 2023
Impact and Cost-Effectiveness of Alternative Human Papillomavirus Vaccines for Preadolescent Girls in Mozambique: A Modelling StudyEsperança Lourenço Guimarães, Assucênio Chissaque, Clint Pecenka, et al.
Pageof 6